

Marek Trneny

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5723114/marek-trneny-publications-by-year.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

210 papers	10,113 citations	39 h-index	99 g-index
232 ext. papers	12,206 ext. citations	5.2 avg, IF	5.35 L-index

#	Paper	IF	Citations
210	The diagnostic performance of whole-body MRI in the staging of lymphomas in adult patients compared to PET/CT and enhanced reference standard-systematic review and meta-analysis.. <i>Quantitative Imaging in Medicine and Surgery</i> , 2022 , 12, 1558-1570	3.6	
209	Immunotherapy and Maintenance With Obinutuzumab or Rituximab in Patients With Previously Untreated Marginal Zone Lymphoma in the Randomized GALLIUM Trial.. <i>HemaSphere</i> , 2022 , 6, e699	0.3	1
208	Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.. <i>New England Journal of Medicine</i> , 2022 , 386, 1421-1431	59.2	2
207	Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.. <i>New England Journal of Medicine</i> , 2021 ,	59.2	21
206	Glofitamab Step-up Dosing Induces High Response Rates in Patients (pts) with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Most of Whom Had Failed Prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy. <i>Blood</i> , 2021 , 138, 130-130	2.2	1
205	Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203). <i>Blood</i> , 2021 , 138, 813-813	2.2	1
204	Real-World Evidence on Therapeutic Strategies and Treatment-Sequencing in Patients with Chronic Lymphocytic Leukemia: An International Study of Eric, the European Research Initiative on CLL. <i>Blood</i> , 2021 , 138, 2635-2635	2.2	0
203	First-Mind: Primary Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 3556-3556	2.2	0
202	The POLARIX Study: Polatuzumab Vedotin with Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 1287-1287	2.2	1
201	End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. <i>Blood Advances</i> , 2021 , 5, 1283-1290	7.8	6
200	Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 2118-2124	4.4	1
199	Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma. <i>Acta Biomaterialia</i> , 2021 , 119, 349-359	10.8	3
198	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 , 21, 267-278.e10	2	1
197	CD31/PECAM-1 impacts engraftment, growth and spread of mantle cell lymphoma cells and positively correlates with extramedullary involvement. <i>Leukemia and Lymphoma</i> , 2021 , 62, 861-867	1.9	0
196	A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. <i>Blood</i> , 2021 , 137, 600-609	2.2	28
195	Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT. <i>Bone Marrow Transplantation</i> , 2021 , 56, 709-712	4.4	
194	Prognostic impact of early-versus-late responses to different induction regimens in patients with myeloma undergoing autologous hematopoietic cell transplantation: Results from the CALM study by the CMWP of the EBMT. <i>European Journal of Haematology</i> , 2021 , 106, 708-715	3.8	

193	Single-nucleotide Fcγ receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. <i>Blood Advances</i> , 2021 , 5, 2935-2944	7.8	0
192	Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. <i>Blood Advances</i> , 2021 , 5, 2945-2957	7.8	1
191	Efficacy and Safety of CT-P10 Versus Rituximab in Untreated Low-Tumor-Burden Follicular Lymphoma: Final Results of a Randomized Phase III Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021 ,	2	2
190	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020 , 4, 6009-6018	7.8	20
189	The interval between progression and therapy initiation is the key prognostic parameter in relapsing diffuse large B cell lymphoma: analysis from the Czech Lymphoma Study Group database (NIHIL). <i>Annals of Hematology</i> , 2020 , 99, 1583-1594	3	
188	A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. <i>Journal of Hematology and Oncology</i> , 2020 , 13, 71	22.4	28
187	Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naïve (TN) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with del(17p): Follow-up Results from Arm C of the SEQUOIA (BGB-3111-304) Trial. <i>Blood</i> , 2020 , 136, 11-12	2.2	13
186	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203). <i>Blood</i> , 2020 , 136, 36-37	2.2	3
185	Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Not Previously Treated with a BTK Inhibitor (CITADEL-205). <i>Blood</i> , 2020 , 136, 22-23	2.2	4
184	Efficacy of Subsequent Novel Targeted Therapies, Including Repeated Venetoclax-Rituximab (VenR), in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Previously Treated with Fixed-Duration Venr in the Murano Study. <i>Blood</i> , 2020 , 136, 44-45	2.2	7
183	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase. <i>Blood</i> , 2020 , 136, 27-28	2.2	1
182	Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (MYD88WT) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2020 , 38, e20056-e20056	2.2	2
181	Zanubrutinib monotherapy for patients with treatment naïve chronic lymphocytic leukemia and 17p deletion. <i>Haematologica</i> , 2020 , 106, 2354-2363	6.6	28
180	Prognostic impact of somatic mutations in diffuse large B-cell lymphoma and relationship to cell-of-origin: data from the phase III GOYA study. <i>Haematologica</i> , 2020 , 105, 2298-2307	6.6	15
179	Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial. <i>Journal of Clinical Oncology</i> , 2020 , 38, 248-256	2.2	29
178	Concurrent and Gene Aberrations in Newly Diagnosed Mantle Cell Lymphoma Correlate with Chemoresistance and Call for Innovative Upfront Therapy. <i>Cancers</i> , 2020 , 12,	6.6	12
177	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020 , 136, 2038-2050	2.2	110
176	A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2020 , 191, e103-e106	4.5	4

175	Rituximab maintenance significantly reduces early follicular lymphoma progressions in patients treated with frontline R-CHOP. <i>EJHaem</i> , 2020 , 1, 170-180	0.9	
174	Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. <i>Blood Advances</i> , 2020 , 4, 1589-1593	7.8	9
173	First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. <i>Annals of Hematology</i> , 2019 , 98, 1961-1972	3	9
172	Prognostic Impact of Natural Killer Cell Count in Follicular Lymphoma and Diffuse Large B-cell Lymphoma Patients Treated with Immunochemotherapy. <i>Clinical Cancer Research</i> , 2019 , 25, 4634-4643	12.9	30
171	Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal in Relapsed Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2019 , 25, 4455-4465	12.9	42
170	First-line imatinib in elderly patients with chronic myeloid leukaemia from the CAMELIA registry: Age and dose still matter. <i>Leukemia Research</i> , 2019 , 81, 67-74	2.7	5
169	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1188-1199	2.2	165
168	Prospective observational study in comorbid patients with chronic lymphocytic leukemia receiving first-line bendamustine with rituximab. <i>Leukemia Research</i> , 2019 , 79, 17-21	2.7	4
167	Tandem Autologous Stem Cell Transplantation Improves Outcomes in Newly Diagnosed Multiple Myeloma with Extramedullary Disease and High-Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 2134-2142	4.7	28
166	Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia. <i>Blood</i> , 2019 , 134, 87-87	2.2	11
165	Subgroup Analyses of Elderly Patients Aged ≥70 Years in AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) vs Rituximab Plus Placebo (R-Placebo) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL). <i>Blood</i> , 2019 , 134, 347-347	2.2	2
164	Sustained Overall Survival Benefit of Obinutuzumab Plus Bendamustine Followed By Obinutuzumab Maintenance Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Final Results of the Gadolin Study. <i>Blood</i> , 2019 , 134, 2888-2888	2.2	1
163	Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019 , 134, 4088-4088	2.2	7
162	A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab + Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: The First-Mind Trial. <i>Blood</i> , 2019 , 134, 2877-2877	2.2	3
161	A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA. <i>Blood</i> , 2019 , 134, 883-883	2.2	0
160	Complete Response Status According to RECIL 2017 Criteria Shows High Concordance with Lugano 2014 Criteria and Is Highly Prognostic for Outcome in Previously Untreated Patients with CD20-Positive Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , 2019 , 134, 489-489	2.2	0
159	Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design. <i>Blood</i> , 2019 , 134, 4101-4101	2.2	0
158	Maintenance rituximab in newly diagnosed mantle cell lymphoma patients: a real world analysis from the Czech lymphoma study group registry. <i>Leukemia and Lymphoma</i> , 2019 , 60, 748-755	1.9	4

157	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. <i>Blood</i> , 2019 , 133, 494-497	2.2	18
156	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019 , 133, 919-926	2.2	44
155	Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. <i>American Journal of Hematology</i> , 2019 , 94, E50-E53	7.1	4
154	ESMO Consensus Conference on malignant lymphoma: general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. <i>Annals of Oncology</i> , 2018 , 29, 544-562	10.3	42
153	Incidence of Second Primary Malignancies after Autologous Transplantation for Multiple Myeloma in the Era of Novel Agents. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 930-936	4.7	9
152	The incidence of biopsy-proven transformation in follicular lymphoma in the rituximab era. A retrospective analysis from the Czech Lymphoma Study Group (CLSG) database. <i>Annals of Hematology</i> , 2018 , 97, 669-678	3	13
151	Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. <i>Hematological Oncology</i> , 2018 , 36, 110-115	1.3	14
150	Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. <i>Cytometry Part B - Clinical Cytometry</i> , 2018 , 94, 121-128	3.4	86
149	A phase II multicenter study of the anti-CD19 antibody drug conjugate coltuximab ravtansine (SAR3419) in patients with relapsed or refractory diffuse large B-cell lymphoma previously treated with rituximab-based immunotherapy. <i>Haematologica</i> , 2018 , 103, 1351-1358	6.6	32
148	Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. <i>Hematological Oncology</i> , 2018 , 36, 773-778	1.3	7
147	AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 445-445	2.2	8
146	Nivolumab for Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) after Autologous Hematopoietic Cell Transplantation (auto-HCT): Extended Follow-up of the Phase 2 Single-Arm CheckMate 205 Study. <i>Blood</i> , 2018 , 132, 2897-2897	2.2	9
145	Nivolumab Treatment Beyond Investigator-Assessed Progression: Extended Follow-up in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 CheckMate 205 Study. <i>Blood</i> , 2018 , 132, 2932-2932	2.2	9
144	Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials. <i>Blood</i> , 2018 , 132, 1605-1605	2.2	1
143	Prognostic Impact of Germ-Line FCGR2A (H131R), FCGR3A (F158V), and FCGR2B (I232T) Single Nucleotide Polymorphisms in Lymphoma Patients Treated with Obinutuzumab or Rituximab in Combination with Chemotherapy: Results from the Phase III GALLIUM and GOYA Clinical Trials. <i>Blood</i> , 2018 , 132, 4109-4109	2.2	2
142	No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study. <i>Blood</i> , 2018 , 132, 783-783	2.2	12
141	Venetoclax Plus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) Improves Outcomes in BCL2-Positive First-Line Diffuse Large B-Cell Lymphoma (DLBCL): First Safety, Efficacy and Biomarker Analyses from the Phase II CAVALLI Study. <i>Blood</i> , 2018 , 132, 782-782	2.2	18
140	Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed/refractory (r/r) FL and DLBCL. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7507-7507	2.2	31

139	A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS7589-TPS7589	2.2	1
138	Co-Targeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Refractory Mantle Cell Lymphoma with Complex Karyotype Changes. <i>Blood</i> , 2018 , 132, 42-42	2.2	
137	Anaplastic Large-Cell Lymphoma Associated with Breast Implants: A Case Report of a Transgender Female. <i>Aesthetic Plastic Surgery</i> , 2018 , 42, 451-455	2	23
136	Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1814-1828	1.9	15
135	Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , 2018 , 180, 224-235	4.5	8
134	Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. <i>Journal of Clinical Oncology</i> , 2018 , 36, 1428-1439	2.2	377
133	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 942-950	2.2	175
132	Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2259-2266	2.2	73
131	Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial. <i>Lancet Haematology,the</i> , 2018 , 5, e543-e553	14.6	38
130	Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018 , 19, 1530-1542	21.7	59
129	downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. <i>Blood</i> , 2018 , 132, 2389-2400	2.2	26
128	The influence of maintenance therapy of rituximab on the survival of elderly patients with follicular lymphoma. A retrospective analysis from the database of the Czech Lymphoma Study Group. <i>Leukemia Research</i> , 2018 , 73, 29-38	2.7	3
127	Hematopoiesis in patients with mature B-cell malignancies is deregulated even in patients with undetectable bone marrow involvement. <i>Haematologica</i> , 2017 , 102, e152-e155	6.6	1
126	Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. <i>Blood</i> , 2017 , 130, 310-322	2.2	66
125	Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis. <i>JAMA Neurology</i> , 2017 , 74, 459-469	17.2	147
124	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2017 , 23, 4127-4137	12.9	98
123	B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma. <i>Blood</i> , 2017 , 129, 333-346	2.2	36
122	Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. <i>New England Journal of Medicine</i> , 2017 , 377, 1331-1344	59.2	365

121	Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3529-3537	2.2	234
120	Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database. <i>Leukemia and Lymphoma</i> , 2017 , 58, 601-613	1.9	6
119	Plasma miR-155, miR-203, and miR-205 are Biomarkers for Monitoring of Primary Cutaneous T-Cell Lymphomas. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	21
118	Nivolumab Treatment Beyond Investigator-Assessed Progression: Outcomes in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma from the Phase 2 Checkmate 205 Study. <i>Blood</i> , 2017 , 130, 650-650	2.2	9
117	Nivolumab for Newly Diagnosed Advanced-Stage Classical Hodgkin Lymphoma (cHL): Results from the Phase 2 Checkmate 205 Study. <i>Blood</i> , 2017 , 130, 651-651	2.2	23
116	Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study. <i>Blood</i> , 2017 , 130, 824-824	2.2	11
115	Impact of rituximab maintenance and maintenance schedule on prognosis in first-line treatment of follicular lymphoma. Retrospective analysis from Czech Lymphoma Study Group (CLSG) database. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1094-103	1.9	7
114	Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1283-94	21.7	643
113	Mantle cell lymphoma-variant Richter syndrome: Detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years. <i>International Journal of Cancer</i> , 2016 , 139, 2252-60	7.5	7
112	Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. <i>Lancet Oncology, The</i> , 2016 , 17, 1081-1093	21.7	224
111	Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. <i>Oncolimmunology</i> , 2016 , 5, e1115940	7.2	43
110	Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. <i>Lancet, The</i> , 2016 , 387, 770-8	40	293
109	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. <i>Lancet Oncology, The</i> , 2016 , 17, 319-331	21.7	103
108	Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , 2016 , 22, 1138-49	12.9	56
107	Significantly higher numbers of proB cells in healthy Caucasians compared to Asians: Is there association with incidence of CLL?. <i>Blood Cells, Molecules, and Diseases</i> , 2016 , 57, 118-9	2.1	1
106	Checkmate 205 Update with Minimum 12-Month Follow up: A Phase 2 Study of Nivolumab in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma. <i>Blood</i> , 2016 , 128, 1110-1110	2.2	33
105	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). <i>Blood</i> , 2016 , 128, 2923-2923	2.2	4
104	Population-Based Analysis of Elderly Patients (>70 YEARS) with Peripheral T-CELL Lymphoma: A Results from Czech Lymphoma Study Group (CLSG) Registry. <i>Blood</i> , 2016 , 128, 3000-3000	2.2	1

103	Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA). <i>Blood</i> , 2016 , 128, 470-470	2.2	20
102	Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study. <i>Blood</i> , 2016 , 128, 6-6	2.2	23
101	Checkmate 205: Nivolumab (nivo) in classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and brentuximab vedotin (BV) a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 7535-7535	2.2	7
100	B-Cell Receptor Driven MALT1 Activity Regulates MYC Signaling in Mantle Cell Lymphoma. <i>Blood</i> , 2016 , 128, 611-611	2.2	
99	Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial. <i>Blood</i> , 2016 , 128, 2978-2978	2.2	
98	Early Progression after R-CHOP in Follicular Lymphoma: Key Role for the Maintenance Therapy. <i>Blood</i> , 2016 , 128, 1779-1779	2.2	
97	Myristoylated Alanine-Rich C-Kinase Substrate (MARCKS) Is a New Biomarker for Mantle Cell Lymphoma: Expression, Localization, and Phosphorylation Study. <i>Blood</i> , 2016 , 128, 1767-1767	2.2	
96	Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2575-82	2.2	106
95	First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , 2016 , 17, 928-942	21.7	416
94	Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2777-2783	1.9	20
93	Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. <i>Lancet Haematology</i> , 2016 , 3, e128-38	14.6	28
92	Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia. <i>Haematologica</i> , 2015 , 100, 511-6	6.6	34
91	Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial. <i>Haematologica</i> , 2015 , 100, 955-63	6.6	60
90	Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. <i>Haematologica</i> , 2015 , 100, e311-4	6.6	12
89	The use of formalin-fixed, paraffin-embedded lymph node samples for the detection of minimal residual disease in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2015 , 169, 145-8	4.5	3
88	Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas. <i>International Journal of Hematology</i> , 2015 , 102, 441-50	2.3	15
87	Treatment of high-risk aggressive B-cell non-Hodgkin lymphomas with rituximab, intensive induction and high-dose consolidation: long-term analysis of the R-MegaCHOP-ESHAP-BEAM Trial. <i>Leukemia and Lymphoma</i> , 2015 , 56, 57-64	1.9	1
86	Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. <i>Hematology</i> , 2015 , 20, 129-36	2.2	4

85	Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?. <i>Leukemia and Lymphoma</i> , 2015 , 56, 2350-6	1.9	20
84	Reproducible Diagnosis of Chronic Lymphocytic Leukemia (CLL) By Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project. <i>Blood</i> , 2015 , 126, 4146-4146	2.2	2
83	Ibrutinib Vs Tamsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2015 , 126, 469-469	2.2	2
82	Outcomes in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous Stem Cell Transplantation (ASCT): An Analysis of Patients Included in the Coral Study. <i>Blood</i> , 2015 , 126, 517-517 ^{2,2}	17 ²	1
81	Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity. <i>Blood</i> , 2015 , 126, 821-821	2.2	1
80	AUGMENT: A randomized, phase 3 trial in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) to compare efficacy and safety of lenalidomide plus rituximab (R2) versus placebo plus rituximab.. <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS8603-TPS8603	2.2	1
79	GADOLIN: Primary results from a phase III study of obinutuzumab plus bendamustine compared with bendamustine alone in patients with rituximab-refractory indolent non-Hodgkin lymphoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, LBA8502-LBA8502	2.2	9
78	Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma. <i>PLoS ONE</i> , 2015 , 10, e0140819	3.7	24
77	Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 8547-8547	2.2	1
76	Prevalence and Prognostic Value of BCL2 and MYC Protein Expression within ABC and GCB Subtypes in Patients with Previously Untreated, Diffuse Large B-Cell Lymphoma: Analysis from the Phase III MAIN Study. <i>Blood</i> , 2015 , 126, 3971-3971	2.2	
75	Mouse models of mantle cell lymphoma, complex changes in gene expression and phenotype of engrafted MCL cells: implications for preclinical research. <i>Laboratory Investigation</i> , 2014 , 94, 806-17	5.9	21
74	Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventional study on usage and side effects of dimethyl sulfoxide. <i>Transfusion</i> , 2014 , 54, 2514-22	2.9	54
73	Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents. <i>Molecular Cancer</i> , 2014 , 13, 159	42.1	22
72	Confirmation of the mantle-cell lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1338-46	2.2	112
71	Microvessel density of mantle cell lymphoma. A retrospective study of its prognostic role and the correlation with the Ki-67 and the mantle cell lymphoma international prognostic index in 177 cases. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014 , 445, 587-97	5.1	10
70	Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database. <i>Leukemia and Lymphoma</i> , 2014 , 55, 802-10	1.9	24
69	R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. <i>Haematologica</i> , 2014 , 99, 1343-9	6.6	64
68	Frontline Chemoimmunotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Shows Superior Efficacy in Comparison to Bendamustine (B) and Rituximab (BR) in Previously Untreated and Physically Fit Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Final Analysis of an International, Randomized Study of the German CLL Study Group (GCLLSG) (CLL10 Study). <i>Blood</i> , 2014 , 124, 19-19	2.2	40

67	The Outcome of Mantle Cell Lymphoma patients after Treatment Failure and Prognostic value of Secondary Mantle Cell International Prognostic Index (sec MIPI). <i>Blood</i> , 2014 , 124, 4425-4425	2.2	3
66	Phase II Randomized, Multicenter Study of Lenalidomide Vs Best Investigator's Choice in Relapsed/Refractory Mantle Cell Lymphoma: Results of the MCL-002 (SPRINT) Study. <i>Blood</i> , 2014 , 124, 626-626	2.2	10
65	Immunomodulatory Agent Lenalidomide Enhances Antitumor Functions of Chimeric Receptor-Modified T Cells in Vitro and in Vivo. <i>Blood</i> , 2014 , 124, 805-805	2.2	2
64	Starlyte phase II study of coltuximab ravtansine (CoR, SAR3419) single agent: Clinical activity and safety in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL; NCT01472887).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8506-8506	2.2	9
63	A new prognostic score for elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: the prognostic role of blood monocyte and lymphocyte counts is absent. <i>PLoS ONE</i> , 2014 , 9, e102594	3.7	20
62	AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS8614-TPS8614	2.2	
61	Hematopoietic Stem and Progenitor Cells in Patients with Mature B-Cell Malignancies Are Quantitatively and Qualitatively Deregulated Compared to Healthy Controls. <i>Blood</i> , 2014 , 124, 4307-4307 ^{2,2}		
60	Defining Criteria for Diagnosis of Occult Lymphomatous Involvement in Cerebrospinal Fluid. <i>Blood</i> , 2014 , 124, 5412-5412	2.2	
59	Observational Study Alternating R-CHOP21 and R-Cytarabine (3+3 Cycles) for Patients with Newly Diagnosed Mantle Cell Lymphoma Not Eligible for High-Dose Therapy: A Czech Lymphoma Study Group Trial Preliminary Results. <i>Blood</i> , 2014 , 124, 1720-1720	2.2	
58	Roscovitine sensitizes leukemia and lymphoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. <i>Leukemia and Lymphoma</i> , 2013 , 54, 372-80	1.9	10
57	Minimal residual disease detectable by quantitative assessment of WT1 gene before allogeneic stem cell transplantation in patients in first remission of acute myeloid leukemia has an impact on their future prognosis. <i>Clinical Transplantation</i> , 2013 , 27, E21-9	3.8	15
56	A randomized study of interferon α versus no treatment as consolidation after high dose therapy and autologous stem cell transplantation for patients with relapsed lymphoma. <i>Oncologist</i> , 2013 , 18, 1189	5.7	5
55	Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels. <i>Cancer Medicine</i> , 2013 , 2, 216-25	4.8	3
54	Impact Of Rituximab Maintenance Schedule On Prognosis In First Line Treatment Of Follicular Lymphoma. Retrospective Analysis From Czech Lymphoma Group (CLG) Database. <i>Blood</i> , 2013 , 122, 4387-4387 ¹		
53	Oncogenic Micrnas In Cerebrospinal Fluid and Sera Reflect Therapy Efficacy and Their Reappearance Precedes Clinical Relapse In Primary and Secondary CNS Lymphoma. <i>Blood</i> , 2013 , 122, 1777-1777	2.2	
52	Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4462-9	2.2	194
51	Intrpleural bortezomib for the therapy of myelomatous pleural effusion: a case report. <i>Case Reports in Immunology</i> , 2012 , 2012, 978479	1.9	6
50	Fludarabine, Cyclophosphamide and Rituximab (FCR) Related Prolonged Cytopenia Is Frequent and Adverse Factor Affecting Survival of Patients with Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2012 , 120, 1790-1790	2.2	

49	Factors Affecting Quality of Life During and After Stem Cell Transplantation in Long Term Survivors [Comparison of Autologous and Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2012 , 120, 590-590	2.2	
48	CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MINT) Group. <i>Lancet Oncology, The</i> , 2011 , 12, 1013-22	21.7	485
47	MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 117, 3816-25	2.2	108
46	Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. <i>European Journal of Haematology</i> , 2011 , 87, 130-7	3.8	14
45	Reply to the letter to the editor by Guinn et al. <i>European Journal of Haematology</i> , 2011 , 87, 470	3.8	
44	The evaluation of survival and proliferation of lymphocytes in autologous mixed leukocyte reaction with dendritic cells. The comparison of incorporation of (3)H-thymidine and differential gating method. <i>Cellular Immunology</i> , 2011 , 271, 78-84	4.4	8
43	Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy. <i>BMC Medical Research Methodology</i> , 2011 , 11, 140	4.7	7
42	Expression patterns of microRNAs associated with CML phases and their disease related targets. <i>Molecular Cancer</i> , 2011 , 10, 41	42.1	92
41	Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?. <i>American Journal of Hematology</i> , 2011 , 86, 318-21	7.1	14
40	No association between the TP53 codon 72 polymorphism and risk or prognosis of Hodgkin and non-Hodgkin lymphoma. <i>Leukemia Research</i> , 2011 , 35, 1117-9	2.7	3
39	Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1668-74	1.9	50
38	Pattern of Mir-155 and PU.1 Expression in CLL/SLL and Aggressive Lymphomas. <i>Blood</i> , 2011 , 118, 4600-4600		
37	Symptoms and Toxicity of Rituximab Maintenance (R-M) Versus Observation (OBS) Following Rituximab Plus Chemotherapy in Patients with Follicular Lymphoma,. <i>Blood</i> , 2011 , 118, 3661-3661	2.2	
36	Activation of Chromatin Structure Upstream PU.1 Gene and in Vitro Differentiation in High Risk Myelodysplastic Syndrome Following 5-Azacytidine,. <i>Blood</i> , 2011 , 118, 3791-3791	2.2	
35	Improving Survival in Patients with Chronic Lymphocytic Leukemia - Population Based Study. <i>Blood</i> , 2011 , 118, 2852-2852	2.2	
34	Analysis of Mantle Cell Lymphoma Patients Reveals Novel Regulatory Circuits Involving MicroRNAs and Their Targets. <i>Blood</i> , 2011 , 118, 4624-4624	2.2	
33	Final analysis of the UKLG LY02 trial comparing 6-8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients . <i>British Journal of Haematology</i> , 2010 , 149, 237-43	4.5	13
32	Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1749-55	2.2	483

31	Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4184-90	2.2	1005
30	PBPC collections: Management, techniques and risks. <i>Transfusion and Apheresis Science</i> , 2010 , 43, 237-43	2.4	12
29	High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 685-93	5	64
28	Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1612-22	1.9	21
27	Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. <i>Blood</i> , 2010 , 115, 3215-23	2.2	200
26	Endothelial cells (EC) and endothelial precursor cells (EPC) kinetics in hematological patients undergoing chemotherapy or autologous stem cell transplantation (ASCT). <i>Hematological Oncology</i> , 2010 , 28, 192-201	1.3	5
25	Final Analysis From the International Trial of Single-Agent Ofatumumab In Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia. <i>Blood</i> , 2010 , 116, 921-921	2.2	6
24	The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses □ Population Based Analysis of 458 Patients Treated Between 2003-2009.. <i>Blood</i> , 2010 , 116, 1239-1239	2.2	1
23	Optimized protocol for gene expression analysis in formalin-fixed, paraffin-embedded tissue using real-time quantitative polymerase chain reaction. <i>Diagnostic Molecular Pathology</i> , 2009 , 18, 176-82		14
22	Rituximab based therapy followed by autologous stem cell transplantation leads to superior outcome and high rates of PCR negativity in patients with indolent B-cell lymphoproliferative disorders. <i>Hematology</i> , 2009 , 14, 187-97	2.2	1
21	The cultivation of human multipotent mesenchymal stromal cells in clinical grade medium for bone tissue engineering. <i>Biomaterials</i> , 2009 , 30, 3415-27	15.6	32
20	Implications of the European Organisation for Research And Treatment Of Cancer (EORTC) guidelines on the use of granulocyte colony-stimulating factor (G-CSF) for lymphoma care. <i>Clinical Drug Investigation</i> , 2009 , 29, 491-513	3.2	6
19	Confirmation of the Mantle Cell Lymphoma International Prognostic Index (MIPI) in An Independent Prospective Patient Cohort.. <i>Blood</i> , 2009 , 114, 138-138	2.2	2
18	Correlation Between Serum Ofatumumab Concentrations, Baseline Patient Characteristics and Clinical Outcomes in Patients with Fludarabine-Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ofatumumab.. <i>Blood</i> , 2009 , 114, 3433-3433	2.2	4
17	First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.. <i>Blood</i> , 2009 , 114, 535-535	2.2	31
16	Independent Predictive Value of PET-CT Pre Transplant in Relapsed and Refractory Patients with CD20 Diffuse Large B-Cell Lymphoma (DLBCL) Included in the CORAL Study.. <i>Blood</i> , 2009 , 114, 881-881	2.2	3
15	Management of Relapsed/Refractory Hodgkin Lymphomas After ASCT in Czech Republic.. <i>Blood</i> , 2009 , 114, 4357-4357	2.2	
14	Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2008 , 112, 325-325	2.2	78

13	Ofatumumab (HuMax-CD20), a Novel CD20 Monoclonal Antibody, Is An Active Treatment for Patients with CLL Refractory to Both Fludarabine and Alemtuzumab or Bulky Fludarabine-Refractory Disease: Results from the Planned Interim Analysis of An International Pivotal Trial. <i>Blood</i> , 2008 , 112, 328-328	2.2	21
12	Mantle Cell Lymphoma International Prognostic Score Is Valid and Confirmed in Unselected Cohort of Patients Treated in Rituximab Era. <i>Blood</i> , 2008 , 112, 3745-3745	2.2	3
11	The Addition of Rituximab Eliminates the Negative Prognostic Impact of PMBCL Compared to DLBCL in Young Patients with CD20-Positive Aggressive Lymphomas Receiving a CHOP-Like Chemotherapy: Results of a Subgroup Analysis of the Mabthera International Trial Group (MInT) Study. <i>Blood</i> , 2008 , 112, 839-839	2.2	2
10	Reduced Intensity Allogeneic Stem Cell Transplantation for Follicular Lymphoma Results in An Improved Progression Free Survival When Compared to Autologous Stem Cell Transplantation. An Analysis from the Lymphoma Working Party of the EBMT. <i>Blood</i> , 2008 , 112, 458-458	2.2	
9	The Rituximab Treatment for Relapsed Follicular Lymphomas Changes the Duration of Subsequent Responses. the Analysis on Behalf of CLSG. <i>Blood</i> , 2008 , 112, 1014-1014	2.2	
8	European MCL Network: An Update on Current First Line Trials.. <i>Blood</i> , 2007 , 110, 388-388	2.2	2
7	Individually determined dosing of filgrastim after autologous peripheral stem cell transplantation in patients with malignant lymphoma--results of a prospective multicentre controlled trial. <i>European Journal of Haematology</i> , 2006 , 77, 493-500	3.8	13
6	Single nucleotide polymorphism in 5'-flanking region of BCL6 is not associated with increased risk of non-Hodgkin's lymphoma. <i>Cancer Letters</i> , 2006 , 238, 142-5	9.9	3
5	CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. <i>Lancet Oncology</i> , 2006 , 7, 379-91	21.7	1567
4	Biallelic IgH rearrangements in patients with indolent lymphoproliferative disorders: molecular and practical implications. <i>Journal of Cellular Physiology</i> , 2004 , 199, 217-26	7	7
3	Rituximab, Fludarabin and Cyclophosphamide Followed by High Dose Therapy with Autologous Stem Cell Rescue Leads to High Molecular Remission Rate in Chronic Lymphocytic Leukemia patients but Relapses Are Observed.. <i>Blood</i> , 2004 , 104, 3480-3480	2.2	1
2	Multiplex single-tube screening for mutations in the Nijmegen Breakage Syndrome (NBS1) gene in Hodgkin's and non-Hodgkin's lymphoma patients of Slavic origin. <i>European Journal of Human Genetics</i> , 2003 , 11, 416-9	5.3	18
1	Aleukemic granulocytic sarcoma with AML1/ETO fusion gene expression and clonal T cell populations. <i>Leukemia Research</i> , 2001 , 25, 1137-42	2.7	6